News

  1. Onyx Pharmaceuticals Initiates Phase 3 Kyprolis™ Head-To-Head Comparison Trial vs. Velcade® In Patients With Relapsed Multiple Myeloma 7/2/2012

    Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced today that the company has begun enrollment in the ENDEAVOR trial, a Phase 3 trial evaluating Kyprolis™ (proposed brand name for carfilzomib) in combination with dexamethasone, versus bortezomib (Velcade®) with dexamethasone in patients with relapsed multiple myeloma.

  2. Sixteenth Patient Dosed In Neuralstem ALS Stem Cell Trial 6/19/2012
  3. Abbott Announces Initiation Of Phase 3 Study Of Elagolix In Patients With Endometriosis 6/5/2012

    Abbott (NYSE: ABT), in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), today announced the initiation of a pivotal Phase 3 clinical trial designed to evaluate the safety and efficacy of elagolix in female patients with endometriosis. Elagolix is an oral gonadotropin-releasing hormone (GnRH) antagonist.

  4. BASi Adds Director Of Discovery Services, Expands West Lafayette Research Collaborative Opportunities 5/15/2012

    BASi (Bioanalytical Systems Inc.) has named David Reynolds as its director of discovery services. Reynolds will oversee studies and staff of the company’s new Discovery Center at corporate headquarters in West Lafayette, Ind.

  5. AstraZeneca To Acquire Ardea Biosciences For $1.26B Including Lead Product Lesinurad In Phase III Development For Gout 4/23/2012

    AstraZeneca and Ardea Biosciences, Inc. (NASDAQ: RDEA) today announced that they have entered into a definitive merger agreement, pursuant to which AstraZeneca will acquire Ardea, a San Diego, California-based biotechnology company focused on the development of small-molecule therapeutics.

  6. Peregrine Launches PS-Targeting Clinical Imaging Program 4/4/2012
    Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment and diagnosis of cancer and infectious diseases, today announced that it has launched a program for its experimental phosphatidylserine (PS)-targeting molecular imaging candidate, 124I-PGN650, for the imaging of multiple solid tumor types.
  7. XARELTO (rivaroxaban) Demonstrates Comparable Efficacy To Standard Of Care For The Treatment And Secondary Prevention Of Venous Blood Clots In Patients With Symptomatic Pulmonary Embolism In Pivotal Phase 3 Study 3/27/2012
    Janssen Research & Development, LLC, (Janssen), announced results of the EINSTEIN-PE study showing that the oral anticoagulant XARELTO (rivaroxaban) was comparable to today’s standard of care in treating patients with acute symptomatic pulmonary embolism (PE) and in preventing development of a secondary venous blood clot (known as venous thromboembolism or VTE).
  8. Merge Healthcare Clinical Trials Division Forms Alliance With AG Mednet 3/21/2012
    Merge Healthcare., a leading provider of enterprise imaging and interoperability solutions and clinical trials software announced a partnership with AG Mednet, a global medical image collection and delivery service, to provide life sciences companies with a full suite of tools to manage imaging clinical trials worldwide.
  9. Celerion And Ricerca Biosciences Announce 'The Biosimilars Alliance' To Offer Clients A More Effective Development Path For Biosimilars 3/1/2012

    Celerion, the premier provider of innovative early stage drug development solutions, and Ricerca Biosciences, a drug safety assessment expert in harnessing external preclinical innovation, announce the formation of “The Biosimilars Alliance”.

  10. FDA Requests Additional Data On Novartis Quadrivalent Meningococcal Conjugate Vaccine, Menveo, For Expanded Use In Infants And Toddlers 2/13/2012
    Novartis has received a Complete Response letter from the US Food and Drug Administration (FDA) on its application for the expanded use of Menveo (Meningococcal [Groups A, C, Y and W-135] Oligosaccharide Diphtheria CRM197 Conjugate Vaccine) in infants and toddlers from 2 months of age.